Inhibition of complement alternative pathway function with antiproperdin monoclonal antibodies

Molecular Immunology

Volumn 37, Issue 5, 2000, Pages 191-201

  Gupta Bansal, Rekha ^a   Parent, J Brian ^a   Brunden, Kurt R ^a  

^a GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

Antibodies; Blood; Complement; Inflammation

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT MEMBRANE ATTACK COMPLEX; HEPARIN; MONOCLONAL ANTIBODY; PROPERDIN; PROTAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLOOD; CARDIOPULMONARY BYPASS; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT INHIBITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; LEUKOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; CARDIOPULMONARY BYPASS; COMPLEMENT C3A; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; HUMANS; LEUKOCYTE ELASTASE; PROPERDIN; RESPIRATORY BURST;

EID: 0033853895     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(00)00047-X     Document Type: Article

References (52)

1. Complement deficiency: Predisposing factor to autoimmune syndromes
2. A one-step purification method for monoclonal antibodies based on salt-promoted adsorption chromatography on a thiophilic adsorbent
3. The structural requirements for complement activation by IgG: Does it hinge on the hinge?
4. 2-plasmin inhibitor-plasmin complexes
5. The electronic aggregometer: A novel device for assessing platelet behavior in blood
6. Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass
7. Complement activation during cardiopulmonary bypass: Evidence for generation of C3a and C5a anaphylotoxin
8. Complement deficiencies
9. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products
10. Properdin: Binding to C3b and stabilization of the C3b-dependent C3 convertase
11. Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg)
12. New procedure for the detection of complement deficiency by ELISA
13. Preparation of monoclonal antibodies: Strategies and procedures
14. Preferential activation and depletion of the alternative complement pathway in burn injury
15. Tubing loops as a model for cardiopulmonary bypass circuits: Both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model
16. Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory
17. C3a and C5a stimulate chemotaxis of human mast cells
18. Complement activation during cardiopulmonary bypass
19. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state
20. The complement system
21. 2 suitable for clinical use from mouse IgG1
22. Alternative complement pathway activation by C4b deposited during classical pathway activation
23. Properdin: Approaching four decades of research
24. A mechanism of activation of the alternative complement pathway by the classical pathway: Protection of C3b from inactivation by covalent attachment to C4b
25. Lucigenin-dependent chemiluminescence as a new assay for NADPH oxidase activity in particulate fractions of human polymorphonuclear leukocytes
26. Therapeutic regulation of the complement system in acute injury states
27. Complement deficiency and disease
28. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion
29. C3 proactivator convertase and its mode of action
30. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway
31. The C3 convertase of the alternative pathway of human complement: Enzymatic properties of the biomolecular proteinase
32. Activation of the alternate pathway of human complement by rabbit cells
33. Kinetic assessment of alternative complement pathway activity in a hemolytic system
34. Early onset of acute pulmonary dysfunction after cardiovascular surgery: Risk factors and clinical outcome
35. Fc receptors
36. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorpeal circulation
37. Role of C3 cleavage in monocyte activation during extracorporeal circulation
38. Deposition of the terminal C5b-9 complex in infarcted areas of human myocardium
39. Initiation of the alternative pathway of complement: Recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins
40. Complement activation during cardiopulmonary bypass in infants and children
41. Profile of complement components in patients with severe burns
42. Soluble human complement receptor type 1 inhibits complement-mediated host defense
43. A new biologic role for C3a and C3a desArg: Regulation of TNF-α and IL-1β synthesis
44. Complement activation in the adult respiratory distress syndrome following cardiopulmonary bypass
45. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
46. A rapid, specific assay for superoxide release from phagocytes in small volumes of whole blood
47. Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications
48. Participation of C3 and its ligands in complement activation
49. Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5
50. Anti-C5 monoclonal antibody therepy prevents collagen-induced arthritis and ameliorates established disease
51. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis
52. Anaphylatoxin C3a but not C3a(desArg) is a chemotaxin for the mouse macrophage cell line J774